Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity.
UDP-glucuronosyltransferases (UGTs) are enzymes involved in the metabolism of steroid hormones, carcinogens, cancer chemotherapy agents, and addictive agents from cigarettes. Because the UGT2B family of genes has been linked to hormonal regulation in human cell lines in vitro, we hypothesized that there may be sex-related differences in the expression and activity of these genes in human tissues. To evaluate whether there are sex differences in UGT2B expression and activity, we examined 103 normal human liver specimens for UGT2B expression by real-time polymerase chain reaction and in vitro glucuronidation activities in human liver microsomes (HLM). Men exhibited an approximately 4-fold higher level of expression of UGT2B17 than women (p = 0.007). Consistent with the increased expression of UGT2B17 in men, HLM from men also had a higher level of glucuronidation activity than HLM from women against three UGT2B17 substrates: 3-fold higher for 17-dihydroexemestane (p = 0.002); 3-fold higher for 3-hydroxycotinine (p < 0.001); and 1.5-fold higher for suberoylanilide hydroxamic acid (p = 0.014). When we stratified by UGT2B17 gene deletion genotype, similar patterns were observed for all three substrates, with HLM from men with the UGT2B17 (+/+) or (+/0) genotypes exhibiting significantly higher levels of glucuronidation activity against all three substrates compared with HLM from women. These data suggest that men have a higher amount of UGT2B17 glucuronidation activity then women. This sex difference in UGT2B17 gene expression and corresponding protein activity could potentially result in different levels of carcinogen detoxification or drug elimination in men versus women.
Gallagher
Carla J
CJ
Department of Pharmacology, Penn State College of Medicine, 500 University Drive, CH69, Hershey, PA 17033, USA.
Balliet
Renee M
RM
Sun
Dongxiao
D
Chen
Gang
G
Lazarus
Philip
P
D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D020719:Glucuronides / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D015778:Minor Histocompatibility Antigens; D012333:RNA, Messenger / Q000032:analysis; D012727:Sex Characteristics
D020719:Glucuronides; D015778:Minor Histocompatibility Antigens; D012333:RNA, Messenger; D014453:Glucuronosyltransferase; C500513:UGT2B17 protein, human
Breast Cancer Res. 2004;6(6):246-54
15535854
J Pharmacol Exp Ther. 2004 Aug;310(2):656-65
15044558
Cancer Res. 2004 Feb 1;64(3):1190-6
14871856
J Exp Med. 2003 May 19;197(10):1279-89
12743171
Pharm Res. 1997 Sep;14(9):1115-21
9327435
J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):301-10
9699884
Genomics. 2004 Oct;84(4):707-14
15475248
Annu Rev Pharmacol Toxicol. 2000;40:581-616
10836148
J Clin Endocrinol Metab. 2004 Oct;89(10):5222-32
15472229
J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):413-23
10419020
Biochemistry. 2001 Apr 3;40(13):3869-81
11300766
Cancer Res. 2009 Apr 1;69(7):2981-9
19318555
J Steroid Biochem Mol Biol. 2000 Oct;74(3):149-55
11086234
Endocrinology. 2006 Nov;147(11):5431-42
16887906
Endocrinology. 2006 Aug;147(8):3843-50
16690804
J Pharmacol Exp Ther. 1980 Oct;215(1):86-91
7452494
Mol Pharmacol. 2009 Aug;76(2):425-39
19487245
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):823-8
17416778
Endocrinology. 1997 Jul;138(7):2998-3005
9202245
Drug Metab Dispos. 2002 Nov;30(11):1257-65
12386133
Pharm Res. 1999 Feb;16(2):191-7
10100302
Drug Metab Pharmacokinet. 2006 Oct;21(5):357-74
17072089
Drug Metab Dispos. 2007 Jan;35(1):121-7
17050650
Trends Endocrinol Metab. 2003 Dec;14(10):473-9
14643063
DNA Cell Biol. 1997 Oct;16(10):1143-54
9364925
Pharmacogenet Genomics. 2010 Oct;20(10):575-85
20697310
Oncogene. 2006 Mar 13;25(11):1659-72
16550166